Introduction and commentary: Paving the way for biosimilars in oncology, part 3: Clinical and economic impact of oncology biosimilars.
Director, Breast Oncology Program Taussig Cancer Institute Cleveland Clinic Cleveland, OH. Electronic address: abrahaj5@ccf.org.
Jame
J
Abraham
D000970:Antineoplastic Agents / Q000737:chemistry*; D059451:Biosimilar Pharmaceuticals / Q000737:chemistry*; D004345:Drug Industry / Q000639:trends; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D059451:Biosimilar Pharmaceuticals